Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

Mirco Bartolomei, Lisa Bodei, Concetta De Cicco, Chiara Maria Grana, Marta Cremonesi, Edoardo Botteri, Silvia Melania Baio, Demetrio Aricò, Maddalena Sansovini, Giovanni Paganelli

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using 90Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Methods: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous 90Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. Results: The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. Conclusion: PRRT with 90Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation.

Original languageEnglish
Pages (from-to)1407-1416
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume36
Issue number9
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Peptide Receptors
Meningioma
Radioisotopes
Therapeutics
Somatostatin Receptors
DOTA-Tyr(3)-90Y-octreotide
Radiotherapy
Recurrence
Growth

Keywords

  • Y-DOTATOC
  • Meningioma
  • Octreotide
  • Peptide receptor radionuclide therapy
  • Somatostatin receptor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. / Bartolomei, Mirco; Bodei, Lisa; De Cicco, Concetta; Grana, Chiara Maria; Cremonesi, Marta; Botteri, Edoardo; Baio, Silvia Melania; Aricò, Demetrio; Sansovini, Maddalena; Paganelli, Giovanni.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, No. 9, 09.2009, p. 1407-1416.

Research output: Contribution to journalArticle

Bartolomei, Mirco ; Bodei, Lisa ; De Cicco, Concetta ; Grana, Chiara Maria ; Cremonesi, Marta ; Botteri, Edoardo ; Baio, Silvia Melania ; Aricò, Demetrio ; Sansovini, Maddalena ; Paganelli, Giovanni. / Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. In: European Journal of Nuclear Medicine and Molecular Imaging. 2009 ; Vol. 36, No. 9. pp. 1407-1416.
@article{ec764fa108fa4710bddea6e273a1dcbb,
title = "Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma",
abstract = "Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using 90Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Methods: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous 90Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. Results: The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66{\%}) and progressive disease in the remaining 10 (34{\%}). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. Conclusion: PRRT with 90Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation.",
keywords = "Y-DOTATOC, Meningioma, Octreotide, Peptide receptor radionuclide therapy, Somatostatin receptor",
author = "Mirco Bartolomei and Lisa Bodei and {De Cicco}, Concetta and Grana, {Chiara Maria} and Marta Cremonesi and Edoardo Botteri and Baio, {Silvia Melania} and Demetrio Aric{\`o} and Maddalena Sansovini and Giovanni Paganelli",
year = "2009",
month = "9",
doi = "10.1007/s00259-009-1115-z",
language = "English",
volume = "36",
pages = "1407--1416",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "9",

}

TY - JOUR

T1 - Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

AU - Bartolomei, Mirco

AU - Bodei, Lisa

AU - De Cicco, Concetta

AU - Grana, Chiara Maria

AU - Cremonesi, Marta

AU - Botteri, Edoardo

AU - Baio, Silvia Melania

AU - Aricò, Demetrio

AU - Sansovini, Maddalena

AU - Paganelli, Giovanni

PY - 2009/9

Y1 - 2009/9

N2 - Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using 90Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Methods: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous 90Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. Results: The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. Conclusion: PRRT with 90Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation.

AB - Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using 90Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Methods: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous 90Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. Results: The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. Conclusion: PRRT with 90Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation.

KW - Y-DOTATOC

KW - Meningioma

KW - Octreotide

KW - Peptide receptor radionuclide therapy

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=68949212314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949212314&partnerID=8YFLogxK

U2 - 10.1007/s00259-009-1115-z

DO - 10.1007/s00259-009-1115-z

M3 - Article

VL - 36

SP - 1407

EP - 1416

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 9

ER -